Patch company NeuroDerm Ltd. today presented positive results on its new dermal patch for the treatment of Parkinson's disease, ND0611, at the 14th Congress of the European Federation of Neurological Societies in Geneva, Switzerland.
The presentation described results of pre-clinical studies and preliminary clinical results of the phase I trial for ND0611, a proprietary drug formula for the continuous administration of carbidopa using a dermal patch. Data showed that, in pre-clinical studies, fluctuations in plasma concentration profiles lessened markedly after continuous administration of ND0611.
The trial found that the patch is both safe and effective.
NeuroDerm VP clinical and regulatory affairs Sheila Oren said, "Following the encouraging safety, tolerability and pharmacokinetic results of the phase I clinical study we look forward to proceeding with the clinical development of ND0611, which represents a novel approach to improving the bioavailability of oral levodopa and might provide a new treatment option with a significant clinical benefit to patients with Parkinson's disease."
NeuroDerm is a graduate of the Ofakim Incubator owned by Capital Point Ltd. (TASE:CPTP), which is one of the investors in the patch company. Capital Point's share rose 17.5% on the TASE today to NIS 6.14.
Published by Globes, Israel business news - www.globes-online.com - on September 28, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010